期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 124, 期 1, 页码 30-39出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI69738
关键词
-
资金
- National Health and Medical Research Council (NHMRC) Principal Research Fellowship
- NHMRC program
- Cancer Council Victoria (CCV)
- Leukaemia Foundation of Australia
- Victorian Breast Cancer Research Consortium
- Victorian Cancer Agency
- CCV Fellowship
Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci. The identification of these enzymes and their partner proteins has driven the rapid development of small-molecule inhibitors that target the cancer epigenome. Herein, we discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis. We examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据